Bristol-Myers Squibb Co BMY shares are trading lower by $5.15 (9.5 percent) at $50.34 in Friday's session. Investors are disappointed that the company will not be pursuing accelerated regulatory approval for its lung cancer drug Opvido/Yervoy.
It has been a rough seven days for the pharmaceutical company, since it peaked on January 10 at $60.45 and ended the session at $59.98. The following day, the issue shed $3 when Merck announced favorable results for Keytruda, which is a competing lung cancer drug.
After holding steady for a few days, the issue tumbled to $49.62 following the surprise announcement. That marks the lowest level for the issue since it put in a trio of lows just above $49.00 in late October. Since making that low, it has returned to the lower $50.00 handle.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.